Introduction
Topics in Anti-Cancer Research new developments in the field of Cancer. Novel drugs as anticancer agents and antimyeloma for the treatment of different types of cancer including myeloma with distinctive mechanism of action.
The current book series deals with the advances of new drugs and new patented targets, agents and synthetic compounds, which will lead to more effective therapies in cancer patients. Recent patent literature reveals the role of estrogen as endocrine disruptor through inhibition of the AF1 Domain of liganded and unliganded Estrogen Receptors (ERs).
Natural and potent synthetic phenazines patent derivatives with substituent groups i.e. alkyl, amide, carboxylic acid, aldehyde, and pyrano groups show potent anticancer activities.
The potential role of ShcA proteins in stimulating metastasis and advancement of cancer will offer the new tools for cancer therapy. New approaches and challenges for cancer stem cell aiming at cancer therapy is included in this volume.
The anti-tumor activity of mono Bcl-2 inhibitors and Bcl-2 inhibitors in combination with rapologs will be a novel beneficial invention for the cure of advanced Renal Cell Carcinoma (RCC) as well as other cancer.
The diversity of researches and topics published in this eBook Series will be valuable for cancer researchers, clinicians and cancer professional’s aiming to develop new anti-cancer targets and patents for the treatment of various cancers.
The topics covered in the Eighth Volume of this series comprise:
- - Novel Drugs for Multiple Myeloma
- - Synthetic Estrogens are Endocrine Disruptors via an Inhibition of the AF1 Domain of ERs
- - Recent Progress of Phenazines as Anticancer Agents
- - ShcA family of adaptor proteins: role in metastasis and cancer progression
- - Cancer stem cell targeting for anticancer therapy: Strategies and challenges
